Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 593

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 593
---
, drug addiction, and Alzheimer’s disease. The Agreement NLS will pay Aexon Labs an upfront payment of $30,000 for the option exclusivity and $170,000 upon execution of the definitive agreement to exercise the option. In addition, Aexon Labs will receive 15% of all proceeds earned by NLS in any future sub -licensingagreements. Other than that, the Aexon Agreement includes several milestone royalty payments to Aexon, as follows: •Milestone payment on termination of first Proof -of-Conceptstudy in OX1R/OX2R KO mice model of narcolepsy: US $100,000 •Milestone payment on issuance of the first Patent Granted in the US that covers the Licensed Product: US $300,000 •Milestone payment on issuance of the second Patent Granted in the US that covers the Licensed Product: US $150,000

| Moore Financial Consulting |

Annex E-39

Royalty rate. NLS Pharmaceutics agrees to pay to Aexon Labs a royalty in the Territory on a country -by-countrybasis equal to: •15% of all Net Amounts earned by Licensee in the Territory if the Patent covers the Licensed Product •5% of all Net Amounts in case the Aexon Labs the corresponding Patent has not been granted to the Product at the time of the time of its Commercialization •If NLS challenges the validity of the Patents, the above Royalty Rates are increased to 30% if the challenge initiated by the NLS is not successful. If the challenge pursued by the Company is successful and leads to reduced royalty rates, the new royalty rates resulting from the challenge shall be immediately applied. Sublicensing NLS agrees to pay Aexon Labs the following percentages of license fees, milestones and royalties received from Sublicensees in consideration for any Sublicense granted for the Licensed Products to include: •15% of all Net Amounts earned by Sublicensee in the Territory if the Patent covers the Licensed Products •5% of all Net Amounts in case the Aexon Labs Patent is not granted yet •If any sublicensee challenges the validity of the patent, the new royalty rate doubles to 30% if the validity of Aexon’s patent is confirmed by the relevant patent office. Recent Advancements On June 2024 the Company announced preclinical results from multiple in vitro studies targeting alpha -synuclein( α -synuclein), specifically the A53T